J L Mitchell1, N J Mutch2. 1. School of Biological Sciences, University of Reading, Reading, UK. 2. Aberdeen Cardiovascular & Diabetes Centre, School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
Abstract
Essentials Plasma Factor XIII, a heterodimer of A and B subunits FXIIIA2 B2 , is a transglutaminase enzyme with a well-established role in haemostasis. Cells of bone marrow and mesenchymal lineage express the FXIII-A gene (F13A1) that encodes the cellular form of the transglutaminase, a homodimer of the A subunits, FXIII-A. FXIII-A was presumed to function intracellularly, however, several lines of evidence now indicate that FXIII-A is externalised by an as yet unknown mechanism This review describes the mounting evidence that FXIII-A is a diverse transglutaminase with many intracellular and extracellular substrates that can participate in an array of biological processes SUMMARY: Factor XIII is a tranglutaminase enzyme that catalyzes the formation of ε-(γ-glutamyl)lysyl isopeptide bonds in protein substrates. The plasma form, FXIII-A2 B2 , has an established function in hemostasis, where its primary substrate is fibrin. A deficiency in FXIII manifests as a severe bleeding diathesis, underscoring its importance in this pathway. The cellular form of the enzyme, a homodimer of the A-subunits, denoted FXIII-A, has not been studied in as extensive detail. FXIII-A was generally perceived to remain intracellular, owing to the lack of a classical signal peptide for its release. In the last decade, emerging evidence has revealed that this diverse transglutaminase can be externalized from cells, by an as yet unknown mechanism, and can cross-link extracellular substrates and participate in a number of diverse pathways. The FXIII-A gene (F13A1) is expressed in cells of bone marrow and mesenchymal lineage, notably megakaryocytes, monocytes/macrophages, dendritic cells, chrondrocytes, osteoblasts, and preadipocytes. The biological processes that FXIII-A is coupled with, such as wound healing, phagocytosis, and bone and matrix remodeling, reflect its expression in these cell types. This review describes the mounting evidence that this cellular transglutaminase can be externalized, usually in response to stimuli, and participate in extracellular cross-linking reactions. A corollary of being involved in these biological pathways is the participation of FXIII-A in pathological processes. In conclusion, the functions of this transglutaminase extend far beyond its role in hemostasis, and our understanding of this enzyme in terms of its secretion, regulation and substrates is in its infancy.
Essentials Plasma Factor XIII, a heterodimer of A and B subunits FXIIIA2 B2 , is a transglutaminase enzyme with a well-established role in haemostasis. Cells of bone marrow and mesenchymal lineage express the FXIII-A gene (F13A1) that encodes the cellular form of the transglutaminase, a homodimer of the A subunits, FXIII-A. FXIII-A was presumed to function intracellularly, however, several lines of evidence now indicate that FXIII-A is externalised by an as yet unknown mechanism This review describes the mounting evidence that FXIII-A is a diverse transglutaminase with many intracellular and extracellular substrates that can participate in an array of biological processes SUMMARY: Factor XIII is a tranglutaminase enzyme that catalyzes the formation of ε-(γ-glutamyl)lysyl isopeptide bonds in protein substrates. The plasma form, FXIII-A2 B2 , has an established function in hemostasis, where its primary substrate is fibrin. A deficiency in FXIII manifests as a severe bleeding diathesis, underscoring its importance in this pathway. The cellular form of the enzyme, a homodimer of the A-subunits, denoted FXIII-A, has not been studied in as extensive detail. FXIII-A was generally perceived to remain intracellular, owing to the lack of a classical signal peptide for its release. In the last decade, emerging evidence has revealed that this diverse transglutaminase can be externalized from cells, by an as yet unknown mechanism, and can cross-link extracellular substrates and participate in a number of diverse pathways. The FXIII-A gene (F13A1) is expressed in cells of bone marrow and mesenchymal lineage, notably megakaryocytes, monocytes/macrophages, dendritic cells, chrondrocytes, osteoblasts, and preadipocytes. The biological processes that FXIII-A is coupled with, such as wound healing, phagocytosis, and bone and matrix remodeling, reflect its expression in these cell types. This review describes the mounting evidence that this cellular transglutaminase can be externalized, usually in response to stimuli, and participate in extracellular cross-linking reactions. A corollary of being involved in these biological pathways is the participation of FXIII-A in pathological processes. In conclusion, the functions of this transglutaminase extend far beyond its role in hemostasis, and our understanding of this enzyme in terms of its secretion, regulation and substrates is in its infancy.
Authors: Anna D Protopopova; Andrea Ramirez; Dmitry V Klinov; Rustem I Litvinov; John W Weisel Journal: J Thromb Haemost Date: 2019-03-14 Impact factor: 5.824
Authors: Boris A Anokhin; William L Dean; Kerrie A Smith; Matthew J Flick; Robert A S Ariëns; Helen Philippou; Muriel C Maurer Journal: FEBS J Date: 2019-08-28 Impact factor: 5.542
Authors: Katalin Gyurina; Bettina Kárai; Anikó Ujfalusi; Zsuzsanna Hevessy; Gábor Barna; Pál Jáksó; Gyöngyi Pálfi-Mészáros; Szilárd Póliska; Beáta Scholtz; János Kappelmayer; Gábor Zahuczky; Csongor Kiss Journal: Front Oncol Date: 2019-10-25 Impact factor: 6.244
Authors: Mari T Kaartinen; Mansi Arora; Sini Heinonen; Aila Rissanen; Jaakko Kaprio; Kirsi H Pietiläinen Journal: Int J Mol Sci Date: 2020-11-05 Impact factor: 5.923
Authors: Martina Leitner; Christian Büchold; Ralf Pasternack; Nikolaus B Binder; Gary W Moore Journal: Int J Mol Sci Date: 2021-01-20 Impact factor: 5.923
Authors: M T Kaartinen; M Arora; S Heinonen; A Hang; A Barry; J Lundbom; A Hakkarainen; N Lundholm; A Rissanen; J Kaprio; K H Pietiläinen Journal: Int J Obes (Lond) Date: 2020-11-21 Impact factor: 5.095
Authors: Mingqing Song; Zachary W Fitch; Kannan P Samy; Benjamin M Martin; Qimeng Gao; Robert Patrick Davis; Francis V Leopardi; Niki Huffman; Robin Schmitz; Gayathri R Devi; Bradley H Collins; Allan D Kirk Journal: Xenotransplantation Date: 2021-02-22 Impact factor: 3.907
Authors: Yu-Chi Shen; Adrienne Niederriter Shami; Lindsay Moritz; Hailey Larose; Gabriel L Manske; Qianyi Ma; Xianing Zheng; Meena Sukhwani; Michael Czerwinski; Caleb Sultan; Haolin Chen; Stephen J Gurczynski; Jason R Spence; Kyle E Orwig; Michelle Tallquist; Jun Z Li; Saher Sue Hammoud Journal: Nat Commun Date: 2021-06-23 Impact factor: 14.919